Pasithea Therapeutics Cor... (KTTA)
NASDAQ: KTTA
· Real-Time Price · USD
0.73
-0.01 (-0.80%)
At close: Oct 15, 2025, 3:58 PM
0.72
-0.63%
After-hours: Oct 15, 2025, 04:00 PM EDT
-0.80% (1D)
| Bid | 0.72 |
| Market Cap | 5.41M |
| Revenue (ttm) | 649.03K |
| Net Income (ttm) | -13.46M |
| EPS (ttm) | -7.13 |
| PE Ratio (ttm) | -0.1 |
| Forward PE | n/a |
| Analyst | n/a |
| Dividends | n/a |
| Ask | 0.77 |
| Volume | 198,666 |
| Avg. Volume (20D) | 129,018 |
| Open | 0.70 |
| Previous Close | 0.74 |
| Day's Range | 0.70 - 0.73 |
| 52-Week Range | 0.65 - 4.57 |
| Beta | 0.27 |
| Ex-Dividend Date | n/a |
About KTTA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KTTA
Website n/a
5 months ago
+11.09%
Pasithea Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
5 months ago
+11.07%
Pasithea Therapeutics shares are trading higher after the company announced initiation of its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004, in adult participants with neurofibromatosis type 1 with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas.
